Florida monoclonal antibody sites have closed following the U.S. Food and Drug Administration’s announcement that Regeneron and Eli Lilly’s treatments shouldn’t be used because they don’t work against the COVID omicron variant.
The FDA revoked the emergency use authorization for both drugs on Monday, but said it could reauthorize their use if they prove to be effective against future variants.
Florida’s health agency doesn’t like the decision, which comes nearly week after Florida opened additional antibody monoclonal sites, including in Miami-Dade, Broward and Palm Beach counties. The sites also have been touted by Gov. Ron DeSantis, who has traveled to some of them to give briefings on their opening.
Read more from our news partner at The Miami Herald.